论文部分内容阅读
观察氨曲南治疗３０例老年人革兰氏阴性杆菌所致下呼吸道感染疗效及其抗菌活性。结果氨曲南对革兰氏阴性菌敏感率为７２．２０％，抗菌活性优于环丙沙星（５９．２％），与舒普深（７８．６％）、头孢他定（７３．４％）以及丁胺卡那霉素（７６．４％）相近，而较秦能（８８．８％）弱。氨曲南１ｇ静脉滴注每８小时１次，疗程５～１３天。结果治愈７例，显效１７例，总有效率为８０％，细菌清除率为７４．２％。治疗中无明显毒副反应，无１例发生菌群失调。结论氨曲南作为窄谱的单环β—内酰胺类抗生素，对革兰氏阴性菌所致的感染具有疗效好、副作用少、不易产生群菌失调等特点。
To observe the curative effect and antibacterial activity of aztreonam on lower respiratory tract infection caused by Gram-negative bacilli in 30 elderly patients. Results Aztreonam showed a sensitivity of 72.20% to Gram-negative bacteria. The antibacterial activity of aztreonam was superior to that of ciprofloxacin (59.2%), with Schmid (78.6%) and ceftazidime (73. 4%) and amikacin (76.4%), but weaker than Qinneng (88.8%). Aztreonam 1g intravenous infusion every 8 hours 1, treatment of 5 to 13 days. Results cured in 7 cases, markedly effective in 17 cases, the total effective rate was 80%, bacterial clearance rate was 74.2%. No significant side effects of treatment, no case of flora occurred imbalance. Conclusion Aztreonam as a narrow-spectrum single-ring β-lactam antibiotics, the infection caused by Gram-negative bacteria with good efficacy, fewer side effects, not easy to produce the characteristics of the group of bacteria disorders.